⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PRLD News
Prelude Therapeutics Incorporated
Polycythemia Vera - Global Drug Pipeline Insight, 2026 | 25+ Therapies Drive JAK2-Targeted Innovation and Late-Stage Partnership Opportunities
globenewswire.com
INCY
MRK
PRLD
SLN
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
globenewswire.com
PRLD
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
globenewswire.com
PRLD
PreludeDx Announces the Publication of the Independent Validation of the AidaBREAST® test in npj Breast Cancer
prnewswire.com
PRLD
Pearl Diagnostics Announces Publication of Clinical Studies Supporting FDA Clearance of MycoMEIA ® Aspergillus Assay
businesswire.com
PRLD
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com
PRLD
Form 8-K
sec.gov
PRLD
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
globenewswire.com
PRLD
Form 8-K
sec.gov
PRLD
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
PRLD